“…MMN has been positioned as a potentially promising biomarker candidate for the diagnosis of pathologies such as schizophrenia (Harms et al, 2014;Nagai et al, 2013) or autism spectrum disorders, including Asperger's syndrome (e.g., O'Connor, 2012). Patients with schizophrenia exhibited a reduced ability to detect acoustic changes reflected in reduced MMN (Fisher, Grant, Smith, Borracci, Labelle, & Knott, 2012;Hong, Moran, Du, O'Donnell, & Summerfelt, 2012;Michie, 2001). Schizophrenia has been associated with alterations in neurotransmission as the one mediated by the NMDA (N-methyl-d-aspartate) receptor (Matsuno et al, 2015).…”